Swiss biotech FluoSphera raises 1.23 million euros for drug testing

Swiss biotech startup FluoSphera has raised 1.23 million euros ($1.34 million) to expand commercial activity and advance its AI-driven imaging platform for pre-clinical drug testing. The funding round was led by Soulmates Ventures, with participation from a Swiss business angel and IndieBio New York.

The Geneva-based company said the proceeds will be used to grow its business development team, deepen collaborations with pharmaceutical companies and CROs, and expand automation and AI capabilities for large-scale image analysis. FluoSphera is already working with international pharma partners and academic laboratories.

FluoSphera’s patented platform allows up to six or seven human tissue models to be tested together in a single well, using fluorescent coding to track each tissue independently. The approach is designed to reveal both efficacy signals and off-target toxicity earlier than traditional two-dimensional cell cultures or animal models.